Moderna (MRNA) Net Income towards Common Stockholders (2017 - 2026)

Moderna has reported Net Income towards Common Stockholders for 10 years, with the latest figure at -$782.0 million in Q2 2026.

• Net Income towards Common Stockholders for Q2 2026 came in at -$782.0 million, up 5.21% year-over-year; the trailing twelve-month figure through Jun 2026 was -$3.2 billion (down 8.54% YoY), and the FY2025 annual result was -$2.8 billion, up 20.75% from the prior year.
• Net Income towards Common Stockholders climbed to -$782.0 million in Q2 2026, from -$1.3 billion in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $3.7 billion in Q1 2022 and troughed at -$3.6 billion in Q3 2023.
• A 5-year average of -$270.0 million and a median of -$803.5 million in 2025 frame the typical range for Net Income towards Common Stockholders.
• The widest annual swing landed in 2022, when Net Income towards Common Stockholders jumped 199.51%; it then plunged 1638.46% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $1.5 billion in 2022, then tumbled by 85.19% to $217.0 million in 2023, then sank by 616.13% to -$1.1 billion in 2024, then advanced by 26.25% to -$826.0 million in 2025, then advanced by 5.33% to -$782.0 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$782.0 million in Q2 2026, -$1.3 billion in Q1 2026, and -$826.0 million in Q4 2025.